BR112015009134A2 - combinação - Google Patents
combinaçãoInfo
- Publication number
- BR112015009134A2 BR112015009134A2 BR112015009134A BR112015009134A BR112015009134A2 BR 112015009134 A2 BR112015009134 A2 BR 112015009134A2 BR 112015009134 A BR112015009134 A BR 112015009134A BR 112015009134 A BR112015009134 A BR 112015009134A BR 112015009134 A2 BR112015009134 A2 BR 112015009134A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- combination
- pharmaceutically acceptable
- acceptable salt
- raf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
resumo patente de invenção: "combinação". a presente invenção refere-se a uma nova combinação compreendendo um inibidor de b-raf, particularmente n-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetiletil)-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobenzenossulfonamida ou um sal farmaceuticamente aceitável da mesma, e/ou o inibidor de mek, n-{3-[3-ciclopropil-5-(2-fluoro-4-iodo-fenilamino)6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetra-hidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida ou um sal ou solvato farmaceuticamente aceitável da mesma, e um inibidor de egfr, adequadamente cetuximabe (erbitux) ou erlotinibe; composições farmacêuticas compreendendo os mesmos e métodos de uso de tais combinações e composições no tratamento de condições nas quais inibição de mek e/ou b-raf e/ou egfr é benéfica, por exemplo, câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261718430P | 2012-10-25 | 2012-10-25 | |
PCT/US2013/066564 WO2014066606A2 (en) | 2012-10-25 | 2013-10-24 | Combination |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015009134A2 true BR112015009134A2 (pt) | 2017-07-04 |
Family
ID=50545472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015009134A BR112015009134A2 (pt) | 2012-10-25 | 2013-10-24 | combinação |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150273057A1 (pt) |
EP (1) | EP2911673A4 (pt) |
JP (1) | JP2016503399A (pt) |
KR (1) | KR20150070393A (pt) |
CN (1) | CN104812391A (pt) |
AU (1) | AU2013334599B2 (pt) |
BR (1) | BR112015009134A2 (pt) |
CA (1) | CA2889530A1 (pt) |
MX (1) | MX2015005307A (pt) |
RU (1) | RU2015119218A (pt) |
WO (1) | WO2014066606A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9181243B2 (en) * | 2013-12-03 | 2015-11-10 | Hangzhou Pushai Pharmaceutical Technology Co. Ltd. | Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof |
KR20160088884A (ko) * | 2013-12-12 | 2016-07-26 | 노파르티스 아게 | 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물 |
WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
CN106470697B (zh) * | 2014-09-16 | 2019-10-25 | 兴盟生物医药(苏州)有限公司 | 抗egfr抗体以及其用途 |
WO2017019279A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
WO2017180461A1 (en) * | 2016-04-15 | 2017-10-19 | Eli Lilly And Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
CR20190002A (es) * | 2016-06-03 | 2019-06-10 | Zhu Alexander Cao | Combinaciones farmacéuticas |
RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
EP4259147A1 (en) * | 2020-12-11 | 2023-10-18 | Erasca, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101006086B (zh) * | 2004-06-11 | 2010-09-29 | 日本烟草产业株式会社 | 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物 |
US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
EP2244714A4 (en) * | 2008-02-08 | 2012-06-06 | Poniard Pharmaceuticals Inc | USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
BR112012003926A2 (pt) * | 2009-08-24 | 2020-08-11 | Genentech Inc | método para identificar um paciente não responsivo ao tratamento com um inibidor de b-raf, método para determinar se um tumor irá responder ao tratamento com um inibidor de b-raf, método para predizer se um paciente será não responsivo ao tratamento com um inibidor de braf específico, kit, método para classificar um tumor de mama, pulmão, cólon, ovário, tiroide, melanoma, ou pancreático e método para identificar um tumor não responsivo ao tratamento com um inibidor de b-raf |
SI2488033T1 (sl) * | 2009-10-16 | 2019-10-30 | Novartis Ag | Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF |
PL2560658T3 (pl) * | 2010-04-21 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Wzmacnianie cytotoksyczności komórkowej zależnej od przeciwciał |
FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
ES2590778T3 (es) * | 2011-02-28 | 2016-11-23 | Calitor Sciences, Llc | Compuestos de quinolina sustituida |
US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
JP6374388B2 (ja) * | 2012-09-21 | 2018-08-15 | インテンシティ セラピューティクス, インク.Intensity Therapeutics, Inc. | 癌の治療方法 |
-
2013
- 2013-10-24 BR BR112015009134A patent/BR112015009134A2/pt not_active IP Right Cessation
- 2013-10-24 WO PCT/US2013/066564 patent/WO2014066606A2/en active Application Filing
- 2013-10-24 AU AU2013334599A patent/AU2013334599B2/en not_active Ceased
- 2013-10-24 EP EP13848440.7A patent/EP2911673A4/en not_active Withdrawn
- 2013-10-24 CN CN201380056222.9A patent/CN104812391A/zh active Pending
- 2013-10-24 JP JP2015539782A patent/JP2016503399A/ja active Pending
- 2013-10-24 US US14/437,231 patent/US20150273057A1/en not_active Abandoned
- 2013-10-24 MX MX2015005307A patent/MX2015005307A/es unknown
- 2013-10-24 KR KR1020157013212A patent/KR20150070393A/ko not_active Application Discontinuation
- 2013-10-24 RU RU2015119218A patent/RU2015119218A/ru not_active Application Discontinuation
- 2013-10-24 CA CA2889530A patent/CA2889530A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014066606A2 (en) | 2014-05-01 |
CA2889530A1 (en) | 2014-05-01 |
WO2014066606A3 (en) | 2014-07-10 |
RU2015119218A (ru) | 2016-12-20 |
MX2015005307A (es) | 2015-07-17 |
WO2014066606A8 (en) | 2015-06-04 |
AU2013334599A1 (en) | 2015-04-30 |
JP2016503399A (ja) | 2016-02-04 |
AU2013334599B2 (en) | 2016-03-10 |
EP2911673A2 (en) | 2015-09-02 |
CN104812391A (zh) | 2015-07-29 |
KR20150070393A (ko) | 2015-06-24 |
US20150273057A1 (en) | 2015-10-01 |
EP2911673A4 (en) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015009134A2 (pt) | combinação | |
BR112015028326A2 (pt) | combinações de um anticorpo anti-pd-l1 e um inibidor de mek e/ou um inibidor de braf | |
EA201290149A1 (ru) | Комбинация | |
BR112013011184A2 (pt) | composições e métodos para tratamento de mielofibrose | |
BR112016011222A2 (pt) | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer | |
BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
EA201590674A1 (ru) | Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич | |
BR112014030424A8 (pt) | Formas cristalinas de um inibidor de quinase de tirosina de bruton | |
EA201290976A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
PH12016502353A1 (en) | Pharmaceutical composition | |
TW201613577A (en) | Pharmaceutical combinations | |
BR112016027674A2 (pt) | Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas | |
MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
BR112012011677A2 (pt) | combinação, kit de combinação e uso de uma combinação | |
PH12016502572A1 (en) | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases | |
EA201690762A1 (ru) | {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек | |
BR112012028887A2 (pt) | associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GLAXO GROUP LIMITED (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS PHARMA AG (CH) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |